Quadratech January 2013 Newsletter -19 December 2012
January 2013 Newsletter is available to download. Special points of interest: 1. Awareness of lupus anticoagulants in drug therapy 2. New product, Entamoeba histolytica IgG 3. Research portfolio grows
Selected Publications Citing 21st Century Biochemicals Custom Antibodies -18 December 2012
Quadratech supplies high quality Epigenetic Peptides and Antibodies, Custom Peptides, Custom Antibodies, Antibodies to Selected Targets and Bioactive Peptides. These have been successfully used in many research laboratories.
Amyloid Precursor Protein (APP) is a transmembrane protein that is predominantly expressed in the brain. Mutations and subsequent cleavages of APP by β-secretase, ϒ-secretase and caspases generated amyloid beta peptides, which have been implicated in the pathogenesis of Alzheimer's disease. Proteolytic action of β-secretase and ϒ-secretase generates amyloid β peptides of 40 or 42 residues. These peptides are susceptible to aggregate and lead to formation of amyloid plaques that characterizes Alzheimer disease.
Bio-Synthesis Inc. Introduces "BNA-NC" -14 December 2012
Bio-Synthesis Inc. Introduces "BNA-NC" - A Third Generation Multi Functional Bridged Nucleic Acid Bio-Synthesis is proud to announce that it has acquired a license from BNA Inc. of Osaka, Japan for the manufacturing and distribution of BNA-NC, a third generation of BNA oligonucleotides. This agreement is valid worldwide and is meant for research use only at this time (Patents JP: 4731324(2011.4.28), USP: 7427672(2008.9.23), EP: 1551905(2012.4.25)).
New Products from Bio-Synthesis: GLYCOPEPTIDES -14 December 2012
Biomedical Applications of Glycopeptides Diagnostics–Glycated peptides can serve as biomarkers to monitor the onset of diseases such as hyperglycemia, diabetes and its complications. Studies have shown that in diabetic patients,proteins including Hemoglobin A, Human Serum Albumin(HSA),Fibrinogen are extensively glycated. Diseases Therapy–age–related neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis have been associated with increased AGE’s formation.Glycopeptides can therefore serve as biological markers to evaluate the efficacy of disease therapy.
Intergrated Solutions: Cell Penetrating Peptides -14 December 2012
Bio-Synthesis is a leading global manufacturer of high quality custom peptides and oligonucleotides. Their expertise includes the ability to design and manufacture advanced peptide-bioplymer bioconjugation for biopharmaceutical, diagnostic, and research applications.
Quadratech 2012 Newsletter Back Issues -14 December 2012
Back issues of Quadratech 2012 newsletters are available for viewing and downloading.
New Assays For Measuring Direct Thrombin Inhibitors in Plasma -07 December 2012
Direct Thrombin Inhibitors (DTIs) have increasing and promising curative, preventive or prophylactic applications in severe clinical situations. Laboratory methods are required for adjustment of drug efficacy and for avoiding overdosage. Specialized calibrated clotting and chromogenic assays for quantitating various DTIs have been developed and compared for their efficacy. Results show excellent performance with Hirudin and analogues, but were not found to be suitable for the Argatroban® usual therapeutic range.
Dabigatran calibrator and control plasmas for drug measurement in plasma, when required Amiral J.1, Stangier J.2, Peyrafitte M.1 1HYPHEN BioMed, research, Neuville sur Oise, France. 2Boehringer Ingelheim Pharma Gmbh & Co KG, Biberach an der Riss, Germany
Highly stable and robust protein S clotting assay validated for easier laboratory practice Amiral J.1, Peyrafitte M.2, Vissac A.M.2 1HYPHEN BioMed, Neuville sur Oise, France. 2HYPHEN BioMed, Research, Neuville sur Oise, France